Reportedly, cetuximab, a chimeric EGFR-targeted monoclonal antibody, inhibited the proliferation of EGFR-overexpressing triple-negative breast cancer (TNBC) cells (106). The gene discussed is EGFR; the disease is triple-negative breast carcinoma.